Anti-sense oligonucleotide against chronic hepatitis B
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Anti-sense oligonucleotide against chronic hepatitis B, covering 2025-12-30 to 2025-12-30. Get the full timeline:
Most recent: Clinical Trial Update: A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy [Phase 2]